Nabriva Therapeutics plc (NBRVF)
Market Cap | 300.00 |
Revenue (ttm) | 29.56M |
Net Income (ttm) | -55.05M |
Shares Out | 3.00M |
EPS (ttm) | -1.84 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | n/a |
Open | 0.0001 |
Previous Close | 0.0001 |
Day's Range | 0.0001 - 0.0001 |
52-Week Range | n/a |
Beta | 1.64 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About NBRVF
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infect... [Read more]
Financial Performance
In 2022, NBRVF's revenue was $36.94 million, an increase of 27.82% compared to the previous year's $28.90 million. Losses were -$57.19 million, 15.6% more than in 2021.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/h/c/press15-2532806.jpg)
Meitheal Pharmaceuticals Expands Specialty Biopharmaceuticals Portfolio with Acquisition of CONTEPO™ (Fosfomycin for Injection) from Nabriva Therapeutics
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic inj...
![](https://cdn.snapi.dev/images/v1/w/u/press12-1698098.jpg)
Nabriva Therapeutics Provides Corporate Update
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations-
![](https://cdn.snapi.dev/images/v1/e/w/9na-1652680.jpg)
Nabriva's stock is up after sharing antibiotic news
Shares of Nabriva Therapeutics Plc NBRV, were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiot...
![](https://cdn.snapi.dev/images/v1/j/b/press14-1652512.jpg)
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects –
![](https://cdn.snapi.dev/images/v1/s/w/press10-1631316.jpg)
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
- Shifted Focus to SIVEXTRO to Enable Cost Cutting -
![](https://cdn.snapi.dev/images/v1/8/2/conf5-1621872.jpg)
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...
![](https://cdn.snapi.dev/images/v1/0/8/conf9-1545347.jpg)
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of i...
![](https://cdn.snapi.dev/images/v1/r/a/conf11-1531830.jpg)
Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of in...
![](https://cdn.snapi.dev/images/v1/o/6/press12-1500005.jpg)
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
- Topline Data Expected First Quarter 2023 - - Topline Data Expected First Quarter 2023 -
![](https://cdn.snapi.dev/images/v1/o/e/press20-1485550.jpg)
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
-Net Product Sales of $8.7M Grew 25% versus Q2 2021-
![](https://cdn.snapi.dev/images/v1/q/b/conf1-1461058.jpg)
Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...
![](https://cdn.snapi.dev/images/v1/m/w/press14-1455719.jpg)
Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals
DUBLIN, Ireland and FORT WASHINGTON, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...
![](https://cdn.snapi.dev/images/v1/a/b/conf13-1372944.jpg)
Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age...
![](https://cdn.snapi.dev/images/v1/c/t/press4-1358161.jpg)
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026-
![](https://cdn.snapi.dev/images/v1/w/p/press16-1356211.jpg)
Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...
![](https://cdn.snapi.dev/images/v1/b/y/conf14-1348909.jpg)
Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...
![](https://cdn.snapi.dev/images/v1/o/7/press11-1315910.jpg)
Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
DUBLIN, Ireland and FORT WASHINGTON, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of in...
![](https://cdn.snapi.dev/images/v1/o/g/press20-1298184.jpg)
Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
-Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth-
![](https://cdn.snapi.dev/images/v1/7/f/conf12-1277687.jpg)
Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of in...
![](https://cdn.snapi.dev/images/v1/m/y/press14-1256297.jpg)
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, March 01, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a...
![](https://cdn.snapi.dev/images/v1/7/p/press8-1190218.jpg)
Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022
— Meeting to Reconvene on March 24, 2022 —
![](https://cdn.snapi.dev/images/v1/g/c/press9-1186930.jpg)
Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders
— Meeting to Reconvene on January 18, 2022 —
![](https://cdn.snapi.dev/images/v1/v/t/press2-1178128.jpg)
Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021
-SIVEXTRO ® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022-
![](https://cdn.snapi.dev/images/v1/s/d/press8-1160413.jpg)
Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021
— Meeting to Reconvene on January 14, 2022 — — Meeting to Reconvene on January 14, 2022 —
![](https://cdn.snapi.dev/images/v1/g/b/conf6-1159537.jpg)
Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...